Table 1.
Demographics and clinical characteristics of the subjects (mean ± SD)
| PD group | Control group | P value | |
|---|---|---|---|
| Age (years) | 65.3 ± 7.6 (48–76) | 65.2 ± 7.3 (50–76) | 0.986 |
| Sex | 12 female, 18 male | 12 female, 18 male | 1.000 |
| Disease duration (years) | 4.9 ± 2.6 | N/A | |
| MDS‐UPDRS III (off) | 27.8 ± 9.1 | N/A | |
| MDS‐UPDRS III (on) | 13.6 ± 8.1 | N/A | |
| Hoehn and Yahr staging | 1.9 ± 0.3 | N/A | |
| Bradykinesia subscale (off) | 14.9 ± 4.9 | N/A | |
| Right side | 10.8 ± 3.0 | ||
| Left side | 3.8 ± 1.9 | ||
| Bradykinesia subscale (on) | 5.6 ± 3.3 | N/A | |
| Right side | 4.1 ± 2.5 | ||
| Left side | 1.5 ± 1.0 | ||
| Mini‐mental state examination | 29.2 ± 1.0 | 29.5 ± 0.8 | 0.205 |
| Levodopa equivalent daily dose (mg) | 443.3 ± 141.8 | N/A |
Age and MMSE were analyzed with a two‐sample t‐test; gender was analyzed with a chi‐square test. MDS‐UPDRS, Movement Disorder Society‐Unified Parkinson's Disease Rating Scale.